SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - whe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:bioRxiv
Egile Nagusiak: Moyo-Gwete, Thandeka, Madzivhandila, Mashudu, Makhado, Zanele, Ayres, Frances, Mhlanga, Donald, Oosthuysen, Brent, Lambson, Bronwen E., Kgagudi, Prudence, Tegally, Houriiyah, Iranzadeh, Arash, Doolabh, Deelan, Tyers, Lynn, Chinhoyi, Lionel R., Mennen, Mathilda, Skelem, Sango, Marais, Gert, Wibmer, Constantinos Kurt, Bhiman, Jinal N, Ueckermann, Veronica, Rossouw, Theresa, Boswell, Michael, de Oliveira, Tulio, Williamson, Carolyn, Burgers, Wendy A, Ntusi, Ntobeko, Morris, Lynn, Moore, Penny L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cold Spring Harbor Laboratory 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941631/
https://ncbi.nlm.nih.gov/pubmed/33688657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.03.06.434193
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak